University of Illinois Cancer Center member and UI Health oncologist Frank Weinberg, MD, PhD, was part of an expert panel that has publishd an update to a 2023 evidence-based guideline on systemic therapy for small cell lung cancer (SCLC).
“Recently, an amendment to the guideline was published … on the basis of the results of the phase III ADRIATIC trial evaluating the efficacy of consolidation immunotherapy after chemoradiotherapy in patients with limited-stage (LS) SCLC and the phase II DeLLphi-301 trial evaluating tarlatamab in relapsed SCLC,” the panel members wrote in a companion article published in JCO Oncology Practice, an American Society of Clinical Oncology (ASCO) journal.
The article,“Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights,” is intended to addresses several questions that clinicians may encounter when following the updated guideline.
Click the button below to read the full article.